WHO ICTRP trial
Phase 1/2 study of IMC-I109V in non-cirrhotic HBeAg-negative chronic hepatitis B…
ACTRN12620000403932 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Recruiting
Key facts
| Trial ID | ACTRN12620000403932 |
|---|---|
| Public title | Phase 1/2 study of IMC-I109V in non-cirrhotic HBeAg-negative chronic hepatitis B (HBV) infection |
| Scientific title | An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Patients with Chronic HBV who are Non-Cirrhotic, Hepatitis B e Antigen-negative, and Virally Suppressed |
| Primary sponsor | Immunocore Ltd |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 1 / Phase 2 |
| Countries | Australia;New Zealand;Hong Kong;United Kingdom;Korea, Republic Of;Romania;Belgium;Poland;Spain |
| Conditions | HBeAg-negative chronic HBV infection; HBeAg-negative chronic HBV infection;Infection - Other infectious diseases;Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon |
| Interventions | The purpose of this study is to test IMCI109V in people with chronic hepatitis B virus (HBV) infection and to assess the safety and effectiveness a new treatment, called IMC-I109V. IMC- I109V has been developed to treat HBV by activating… |
| Registration date | Mar 25, 2020 |
| Target size | 80 |
| Secondary IDs | IMC-I109V-101 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: